Navigation Links
StriVectin® Receives Annual Skin Sense Award
Date:10/12/2011

NEW YORK, Oct. 12, 2011 /PRNewswire/ -- StriVectin®, the clinical anti-aging expert, was one of three honorees to receive The Skin Cancer Foundation's 2011 Skin Sense Award Tuesday night at The Plaza. The award, presented at the Foundation's annual gala, honors exceptional achievement in skin health.  The company was recognized for its exclusive NIA-114™ molecule, a multi-patented, proprietary technology rooted in 30 years of research into DNA repair and skin cancer prevention.  Bringing a new level of medical research and rigor to skin care, StriVectin's NIA-114™ technology yields exceptional anti-aging and skin repair results and is clinically proven to reverse the visible effects of skin damage over time.  

"Our mission is to repair and rebuild healthy skin layers, because our belief is that healthy skin is truly the most beautiful skin," said Melisse Shaban, CEO of StriVectin, in accepting the award.  "StriVectin is immensely proud to be bringing these discoveries to the world in unique and novel ways, and we are committed to supporting The Skin Cancer Foundation and the important work they do in the areas of awareness and research."

About StriVectin's Technology:

The development of StriVectin's exclusive Niacin (Vitamin B3) molecule called NIA-114™ is the result of over 30 years of research by Drs. Myron and Elaine Jacobson, noted biochemists, and members of the Arizona Cancer Center.  It all started with their studies on the mechanisms by which cells naturally avoid the development of skin cancer that led to their findings that niacin has many functions in skin cells.  Over many years, including research partially funded by the National Institutes of Health, they continued to study how niacin is involved in how cells respond to DNA damage.  

With more than 14 clinical studies involving 600 subjects and 57 global patents, its unique and unrivaled mechanisms of benefit to skin, its superb safety and tolerability with no side effects, and its compatibility with other potent skin care actives, NIA-114™ is poised to be a dominant skin care technology for years to come.  In fact, NIA-114™ is so effective it has been chosen by the National Cancer Institute for further study as a possible skin cancer prevention agent.

StriVectin products are available at department store and specialty retailers nationwide, and at strivectin.com.

About The Skin Cancer Foundation

The Skin Cancer Foundation is the only global organization solely devoted to the prevention, early detection and treatment of skin cancer. The mission of the Foundation is to decrease the incidence of skin cancer through public and professional education and research. For more information, visit www.SkinCancer.org.

About StriVectin®

StriVectin® is the largest independent prestige skin care company, focusing on clinical anti-aging skin care solutions. Backed by science and rigorous clinical validation, StriVectin is at the forefront of skin care technology and product innovation.  Its unique dual-use repair cream StriVectin-SDTM Intensive Concentrate for Stretch Marks and Wrinkles is a best-seller around the world, and is often credited with starting the clinical cosmeceutical skin care category. StriVectin products are sold through department stores and specialty retailers in North America, Europe, the Middle East and Asia. The company maintains corporate offices in New York, NY, and Raleigh, NC, and research facilities in Tucson, AZ.  For more information, visit strivectin.com


'/>"/>
SOURCE StriVectin(R)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
2. CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM®
3. Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody
4. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
5. JCM Receives the Approval for its Manufacturing Environmental Assessment
6. OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System
7. University of Houston receives NSF grant for high school teachers program
8. GeNO LLC Receives Federal Grant To Advance Studies of Inhaled Nitric Oxide Product for the Treatment of Chronic Pulmonary Diseases
9. Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
10. KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark
11. Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... DIEGO , Feb. 3, 2016   ... company with the first pluripotent stem cell-derived islet ... diabetes in clinical-stage development, today announced that ViaCyte ... Pharmaceutical Companies of Johnson & Johnson, have agreed ... group into ViaCyte.  The agreement provides ViaCyte with ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma ... company that applies its innovative TransCon technology to address ... at an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare ... Date:  , Wednesday, February 10, 2016 Time:  , ... www.ascendispharma.com . --> An audio webcast of ...
(Date:2/3/2016)... Colorado (PRWEB) , ... February 03, 2016 , ... ... hospitals, has established a new office dedicated to the North American healthcare market. ... turnkey solutions to healthcare facilities. The company will provide new pneumatic tube ...
(Date:2/3/2016)... ... February 03, 2016 , ... Resilinc ... summarizes and analyzes nearly 750 unique supply chain notifications and alerts generated by ... , Supply chain risk management practitioners subscribe to the EventWatch service to receive ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):